IGF antagonist peptides
US7071300B2 · kind B2 · utility
8Cited by
5References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2002 |
| Grant date | Jul 4, 2006 |
| Priority date | — |
| Expiry date | May 4, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2299/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.